Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.

Petri MankinenTuomas LundströmErkki SoiniMarja-Liisa SumelahtiJuhani RuutiainenUlla NiskalaElina Järvinen

Published in: Advances in therapy (2019)

Based on the CAM, cladribine tablets were projected to robustly save modelled drug-associated costs in comparison to fingolimod, natalizumab and their mix in Finland.

Keyphrases

multiple sclerosis
white matter
climate change
adverse drug
emergency department
rheumatoid arthritis